SNGX

Soligenix's stock price has experienced significant volatility and a substantial decline over the past six months. Key events impacting the stock include the halting of the Phase 3 FLASH2 trial for HyBryte™ due to futility, which led to a significant drop in stock price. Positive clinical results from a comparative study evaluating HyBryte™ against Valchlor® in CTCL were published, having a minor negative impact on the stock. Soligenix announced recent accomplishments and year-end 2025 financial results, which saw an increase in stock price. The company received Orphan Drug Designation from the European Commission for SGX945 for the treatment of Behçet's Disease. Soligenix announced recent updates and first-quarter 2026 financial results, reporting a net loss of $2.8 million with no revenue, and stated substantial doubt about its ability to continue as a going concern without additional financing. Soligenix experienced substantial shareholder dilution, with total shares outstanding increasing significantly.